Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cocrystal Pharma, Inc. (COCP)

1.96   -0.07 (-3.45%) 09-27 16:00
Open: 2.0701 Pre. Close: 2.03
High: 2.1 Low: 1.93
Volume: 12,060 Market Cap: 20(M)

Technical analysis

as of: 2023-09-27 4:18:29 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 3.14     One year: 3.78
Support: Support1: 1.79    Support2: 1.49
Resistance: Resistance1: 2.68    Resistance2: 3.24
Pivot: 2.02
Moving Average: MA(5): 1.99     MA(20): 2.2
MA(100): 2.5     MA(250): 2.44
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 26.4     %D(3): 17.4
RSI: RSI(14): 36.6
52-week: High: 3.72  Low: 1.74
Average Vol(K): 3-Month: 32 (K)  10-Days: 20 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ COCP ] has closed above bottom band by 26.2%. Bollinger Bands are 57.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.18 - 2.19 2.19 - 2.2
Low: 2.01 - 2.02 2.02 - 2.03
Close: 2.11 - 2.13 2.13 - 2.14

Company Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Headline News

Tue, 26 Sep 2023
Is Cocrystal Pharma Inc (COCP) Stock About to Get Hot Tuesday? - InvestorsObserver

Mon, 14 Aug 2023
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs - Yahoo Finance

Tue, 08 Aug 2023
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead - Yahoo Finance

Wed, 24 May 2023
HC Wainwright & Co. Maintains Cocrystal Pharma (COCP) Buy ... - Nasdaq

Mon, 24 Apr 2023
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan ... - BioSpace

Mon, 10 Apr 2023
PXD, TGTX and EH among pre-market gainers - Seeking Alpha

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 10 (M)
Shares Float 7 (M)
% Held by Insiders 30 (%)
% Held by Institutions 7.2 (%)
Shares Short 15 (K)
Shares Short P.Month 31 (K)

Stock Financials

EPS -2.3
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.41
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -27.8
Return on Equity (ttm) -46.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.92
Qtrly Earnings Growth 0
Operating Cash Flow -22 (M)
Levered Free Cash Flow -15 (M)

Stock Valuations

PE Ratio -0.86
PEG Ratio 0
Price to Book value 0.57
Price to Sales 0
Price to Cash Flow -0.89

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.